{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:03:51Z","timestamp":1793822631594,"version":"4.6.1"},"reference-count":97,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:sec id=\"ab-jrv250038-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>IgA nephropathy (IgAN) is a chronic kidney disease involving deposition of IgA-containing immune complexes in the glomerulus, causing glomerular inflammation and scarring. It is the most common immune-mediated glomerular disease worldwide, and affects an estimated 198\u202f887 to 208\u202f184 persons in the US. Up to 50% of patients with IgAN develop kidney failure within 10 years of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250038-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>IgAN typically presents with nephritic syndrome and usually occurs in younger adults, with a mean age at diagnosis of 34 to 45 years. Incidence is highest in East Asia. Approximately 60% of cases are detected incidentally with hematuria or proteinuria on urinalysis. Up to 30% of patients present with episodic visible hematuria, often concomitantly with an upper respiratory or gastrointestinal tract infection (synpharyngitic hematuria). Less common presentations include nephrotic syndrome (&amp;amp;lt;5%) and rapidly progressive glomerulonephritis (&amp;amp;lt;5%). When IgAN is suspected (due to hematuria, proteinuria, or reduced kidney function), initial workup should include quantification of proteinuria and assessment for other causes of nephritic syndrome (eg, lupus nephritis). Adults with suspected IgAN and proteinuria greater than or equal to 0.5 g per day should undergo kidney biopsy. The diagnosis of primary IgAN is based on presence of IgA-dominant immune deposits in the glomerular mesangium after excluding other causes of this histologic appearance, ie, IgA vasculitis, IgA-dominant infection-related glomerulonephritis, and secondary IgAN from diseases such as cirrhosis, inflammatory bowel disease, celiac disease, infection (eg, viral hepatitis), and autoimmune diseases (eg, axial spondyloarthritis). Based on the Kidney Disease: Improving Global Outcomes 2025 clinical practice guideline for the management of IgAN, treatment for patients with proteinuria greater than 0.5 g per day includes behavioral modifications (eg, dietary sodium &amp;amp;lt;2 g\/d, smoking cessation, weight control, exercise), antihypertensive medications for goal blood pressure less than 120\/70 mm Hg, and therapies to reduce the formation of IgA-containing immune complexes (eg, targeted-release budesonide), decrease glomerular injury (eg, systemic glucocorticoids, iptacopan), and manage existing IgAN-induced nephron loss (eg, renin-angiotensin system inhibitor or dual endothelin angiotensin receptor antagonist [eg, sparsentan] alone or in combination with a sodium-glucose cotransporter 2 inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250038-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>IgAN is the leading cause of immune-mediated glomerular disease worldwide. Patients with suspected IgAN and proteinuria greater than or equal to 0.5 g per day should undergo kidney biopsy to confirm the diagnosis. Treatment of IgAN includes behavioral modifications, blood pressure management, and therapies to decrease formation of IgA-containing immune complexes (eg, targeted-release budesonide), reduce immune complex\u2013mediated glomerular injury (eg, systemic glucocorticoids, iptacopan), and manage IgAN-induced nephron loss (eg, renin-angiotensin system inhibitor, dual endothelin angiotensin receptor antagonist, and sodium-glucose cotransporter 2 inhibitor).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.25020","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:00:24Z","timestamp":1769443224000},"page":"799","source":"Crossref","is-referenced-by-count":29,"title":["IgA Nephropathy in Adults"],"prefix":"10.1001","volume":"335","author":[{"given":"Sinead","family":"Stoneman","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Wei","family":"Teh","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Galway, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Marie","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Galway, Galway, Ireland"},{"name":"School of Medicine, University of Galway, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jrv250038r1","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy.","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"jrv250038r2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy.","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"2","key":"jrv250038r3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"jrv250038r4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy.","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"jrv250038r5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study.","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"jrv250038r6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"jrv250038r7","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy.","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"jrv250038r8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"jrv250038r9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy.","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"jrv250038r10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey.","volume":"33","author":"O\u2019Shaughnessy","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"jrv250038r11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/ki.1994.384","article-title":"Epidemiology of primary glomerular diseases in a French region: variations according to period and age.","volume":"46","author":"Simon","year":"1994","journal-title":"Kidney Int"},{"issue":"3","key":"jrv250038r12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021.","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"4s","key":"jrv250038r13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobin A vasculitis (IgAV).","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"issue":"2","key":"jrv250038r14","first-page":"139","article-title":"Increase in proteinuria and\/or microhematuria following upper respiratory tract infections in patients with IgA nephropathy.","volume":"9","author":"Miura","year":"1984","journal-title":"Tokai J Exp Clin Med"},{"issue":"3","key":"jrv250038r15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients.","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"jrv250038r16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.ajkd.2024.04.015","article-title":"Chronic tonsillitis and IgA nephropathy: findings from a nationwide Japanese cohort study.","volume":"84","author":"Nakayama","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"8888","key":"jrv250038r17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0140-6736(94)90875-3","article-title":"Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy.","volume":"343","author":"Suzuki","year":"1994","journal-title":"Lancet"},{"key":"jrv250038r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107085","author":"Zhong","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"jrv250038r19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ndt\/gfn441","article-title":"Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy.","volume":"24","author":"Lai","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"jrv250038r20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.","volume":"19","author":"Gharavi","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"jrv250038r21","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan.","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"jrv250038r22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ndt\/gfae143","article-title":"Clinical and histological comparison of IgA nephritis and renal IgA vasculitis.","volume":"40","author":"Friedrich","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"jrv250038r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2025.151571","article-title":"IgA vasculitis and IgA nephropathy: two sides of the same coin?","volume":"44","author":"Pillebout","year":"2024","journal-title":"Semin Nephrol"},{"issue":"1","key":"jrv250038r24","first-page":"68","article-title":"Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake.","volume":"70","author":"Amore","year":"1994","journal-title":"Lab Invest"},{"issue":"6590","key":"jrv250038r25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/bmj.295.6590.78","article-title":"IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger\u2019s disease).","volume":"295","author":"Fornasieri","year":"1987","journal-title":"BMJ (Clin Res Ed)"},{"issue":"10","key":"jrv250038r26","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","article-title":"The incidence and prevalence of IgA nephropathy in Europe.","volume":"38","author":"Willey","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"jrv250038r27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/nep.12559","article-title":"Epidemiology of biopsy-proven glomerulonephritis in Queensland adults.","volume":"21","author":"Jegatheesan","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"jrv250038r28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5414\/CNP74372","article-title":"The changing pattern of primary glomerulonephritis in Singapore and other countries over the past 3 decades.","volume":"74","author":"Woo","year":"2010","journal-title":"Clin Nephrol"},{"issue":"2","key":"jrv250038r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541869","article-title":"Incidence of adult primary immunoglobulin A nephropathy among a racially\/ethnically diverse population in the United States.","volume":"56","author":"Sim","year":"2025","journal-title":"Am J Nephrol"},{"issue":"1","key":"jrv250038r30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5414\/CN111489","article-title":"The incidence and prevalence of immunoglobulin A nephropathy in the United States.","volume":"103","author":"DeCongelio","year":"2025","journal-title":"Clin Nephrol"},{"issue":"6","key":"jrv250038r31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/ndt\/gfq655","article-title":"Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database.","volume":"26","author":"Okpechi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"jrv250038r32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy.","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"jrv250038r33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ndt\/gfx058","article-title":"Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis.","volume":"33","author":"Guti\u00e9rrez","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"jrv250038r34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-016-0959-4","article-title":"IgA vasculitis in adults: the performance of the EULAR\/PRINTO\/PRES classification criteria in adults.","volume":"18","author":"Hocevar","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"jrv250038r35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0046-8177(03)00424-6","article-title":"IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy.","volume":"34","author":"Nasr","year":"2003","journal-title":"Hum Pathol"},{"issue":"1","key":"jrv250038r36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","article-title":"Secondary IgA nephropathy.","volume":"28","author":"Pouria","year":"2008","journal-title":"Semin Nephrol"},{"issue":"4","key":"jrv250038r37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","article-title":"Secondary IgA nephropathy.","volume":"94","author":"Saha","year":"2018","journal-title":"Kidney Int"},{"issue":"7","key":"jrv250038r38","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.3390\/jcm12072726","article-title":"Secondary IgA nephropathy and IgA-associated nephropathy: a systematic review of case reports.","volume":"12","author":"Tota","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"jrv250038r39","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2215\/CJN.0000000000000457","article-title":"Association of inflammatory bowel disease with incident IgA nephropathy.","volume":"19","author":"Nakayama","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"jrv250038r40","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/bjd.14961","article-title":"The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study.","volume":"176","author":"Grewal","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"jrv250038r41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12882-021-02425-8","article-title":"Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a single-center longitudinal study.","volume":"22","author":"Sato","year":"2021","journal-title":"BMC Nephrol"},{"issue":"5","key":"jrv250038r42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0272-6386(87)80143-9","article-title":"Significance of IgA deposits on the glomerular capillary walls in IgA nephropathy.","volume":"9","author":"Yoshimura","year":"1987","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"jrv250038r43","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy.","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"jrv250038r44","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"jrv250038r45","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy.","volume":"28","author":"Sevillano","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"jrv250038r46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.","volume":"35","author":"Shi","year":"2012","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"jrv250038r47","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-021-02978-5","article-title":"Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.","volume":"54","author":"Wang","year":"2022","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"jrv250038r48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12882-021-02453-4","article-title":"Cigarette smoking may accelerate the progression of IgA nephropathy.","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Nephrol"},{"issue":"11","key":"jrv250038r49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233199","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy.","volume":"15","author":"Neves","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"jrv250038r50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12882-024-03839-w","article-title":"Association between different proportions of crescents and the progression of IgA nephropathy (IgAN): a systematic review and meta-analysis.","volume":"25","author":"Yu","year":"2024","journal-title":"BMC Nephrol"},{"issue":"5","key":"jrv250038r51","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy.","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"jrv250038r52","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","article-title":"Long-term outcomes of IgA nephropathy in China.","volume":"40","author":"Shen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"jrv250038r53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12882-025-03958-y","article-title":"Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up.","volume":"26","author":"Rivedal","year":"2025","journal-title":"BMC Nephrol"},{"issue":"2","key":"jrv250038r54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study.","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"jrv250038r55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"jrv250038r56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ki.2011.126","article-title":"Validation of the Oxford classification of IgA nephropathy.","volume":"80","author":"Herzenberg","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"jrv250038r57","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"jrv250038r58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the international IgA Nephropathy Prediction Tool one or two years post-biopsy.","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"issue":"4S","key":"jrv250038r59","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases.","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"10405","key":"jrv250038r60","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"jrv250038r61","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial.","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"jrv250038r62","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial.","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jrv250038r63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial.","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"jrv250038r64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy.","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250038r65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub3","article-title":"Non-immunosuppressive treatment for IgA nephropathy.","volume":"2","author":"Tunnicliffe","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv250038r66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"jrv250038r67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.","volume":"12","author":"Judge","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10417","key":"jrv250038r68","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"jrv250038r69","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy.","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"issue":"4S","key":"jrv250038r70","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"3S","key":"jrv250038r71","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"5","key":"jrv250038r72","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The gut-renal connection in IgA nephropathy.","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin Nephrol"},{"issue":"12","key":"jrv250038r73","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1681\/ASN.2006060658","article-title":"O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy.","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"jrv250038r74","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2249.1995.tb03724.x","article-title":"Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.","volume":"100","author":"Allen","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"jrv250038r75","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"5","key":"jrv250038r76","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial.","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"jrv250038r77","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1002\/jcb.27648","article-title":"Efficacy and safety of angiotensin-converting enzyme inhibitors\/angiotensin receptor blocker therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.","volume":"120","author":"Ji","year":"2019","journal-title":"J Cell Biochem"},{"issue":"6","key":"jrv250038r78","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"jrv250038r79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000013619","article-title":"Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.","volume":"20","author":"Nakamura","year":"2000","journal-title":"Am J Nephrol"},{"issue":"5","key":"jrv250038r80","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"jrv250038r81","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults.","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"jrv250038r82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy: interim analysis of a phase 3 trial.","author":"Perkovic","journal-title":"N Engl J Med"},{"key":"jrv250038r83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy.","author":"Lafayette","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv250038r84","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/ndt\/gfz152","article-title":"Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.","volume":"35","author":"Cassol","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"jrv250038r85","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ki.2009.427","article-title":"IgA nephropathy at two score and one.","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"issue":"25","key":"jrv250038r86","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy.","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv250038r87","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"issue":"6","key":"jrv250038r88","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ndt\/gfm913","article-title":"Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy.","volume":"23","author":"Shimozato","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"jrv250038r89","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00011-023-01848-3","article-title":"Identification of inflammatory biomarkers in IgA nephropathy using the NanoString technology: a validation study in Caucasians.","volume":"73","author":"Gaumond","year":"2024","journal-title":"Inflamm Res"},{"issue":"1","key":"jrv250038r90","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12882-024-03574-2","article-title":"Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy.","volume":"25","author":"Yoon","year":"2024","journal-title":"BMC Nephrol"},{"issue":"2","key":"jrv250038r91","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"jrv250038r92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.769802","article-title":"Urinary soluble CD163 levels predict IgA nephropathy remission status.","volume":"12","author":"Gong","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"jrv250038r93","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.ekir.2024.07.031","article-title":"Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy.","volume":"9","author":"Li","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"jrv250038r94","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"jrv250038r95","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","article-title":"Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.","volume":"30","author":"Yasutake","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"jrv250038r96","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae395","article-title":"Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity.","volume":"18","author":"Nurmi","year":"2024","journal-title":"Clin Kidney J"},{"issue":"1","key":"jrv250038r97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2844446\/jama_stoneman_2026_rv_250038_1771885781.65887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:00:35Z","timestamp":1772553635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2844446"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.25020","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}